+

WO1996017869A3 - Antagonistes d'interleukine-6 (il-6) - Google Patents

Antagonistes d'interleukine-6 (il-6) Download PDF

Info

Publication number
WO1996017869A3
WO1996017869A3 PCT/IT1995/000208 IT9500208W WO9617869A3 WO 1996017869 A3 WO1996017869 A3 WO 1996017869A3 IT 9500208 W IT9500208 W IT 9500208W WO 9617869 A3 WO9617869 A3 WO 9617869A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonists
shil
asn
abnormal
interleukin
Prior art date
Application number
PCT/IT1995/000208
Other languages
English (en)
Other versions
WO1996017869A2 (fr
Inventor
Gennaro Ciliberto
Carlo Toniatti
Original Assignee
Angeletti P Ist Richerche Bio
Gennaro Ciliberto
Carlo Toniatti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio, Gennaro Ciliberto, Carlo Toniatti filed Critical Angeletti P Ist Richerche Bio
Priority to JP8517466A priority Critical patent/JPH09503232A/ja
Priority to AU41866/96A priority patent/AU4186696A/en
Priority to EP95940401A priority patent/EP0742794A1/fr
Publication of WO1996017869A2 publication Critical patent/WO1996017869A2/fr
Publication of WO1996017869A3 publication Critical patent/WO1996017869A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Antagonistes d'interleukine-6 (IL-6) caractérisés en ce qu'ils sont constitués de formes solubles du récepteur α de l'IL-6 humaine (shIL-6Rα) renfermant une ou plusieurs mutations au niveau de l'interface de liaison gp130. Selon le mode préféré de réalisation, les mutations sont présentes dans une position choisie dans le groupe qui comporte Ala 228, Asn 230, His 280 et Asp 281. Ces antagonistes sont utilisables comme agents permettant la prophylaxie et le traitement des maladies dues à une activité anormale de l'IL-6. La figure 4 représente l'activité antagoniste du mutant Ala228Asp/Asn 230Asp/His280Ser/Asp281Val en comparaison avec les propriétés agonistes du shIL-6Rα de type sauvage. Cet antagoniste est utilisable dans la préparation de médicaments destinés à la prophylaxie, à la maîtrise et au traitement des maladies dues à une bioactivité anormale de l'IL-6.
PCT/IT1995/000208 1994-12-06 1995-12-05 Antagonistes d'interleukine-6 (il-6) WO1996017869A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP8517466A JPH09503232A (ja) 1994-12-06 1995-12-05 ＧＰ１３０結合界面で突然変異したインターロイキン−６（ＩＬ−６）受容体αの可溶性型であるＩＬ−６アンタゴニスト
AU41866/96A AU4186696A (en) 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists
EP95940401A EP0742794A1 (fr) 1994-12-06 1995-12-05 Antagonistes d'interleukine-6 (il-6)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM940794A IT1274350B (it) 1994-12-06 1994-12-06 Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
ITRM94A000794 1994-12-06

Publications (2)

Publication Number Publication Date
WO1996017869A2 WO1996017869A2 (fr) 1996-06-13
WO1996017869A3 true WO1996017869A3 (fr) 1996-08-29

Family

ID=11402851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT1995/000208 WO1996017869A2 (fr) 1994-12-06 1995-12-05 Antagonistes d'interleukine-6 (il-6)

Country Status (7)

Country Link
EP (1) EP0742794A1 (fr)
JP (1) JPH09503232A (fr)
CN (1) CN1139933A (fr)
AU (1) AU4186696A (fr)
CA (1) CA2177837A1 (fr)
IT (1) IT1274350B (fr)
WO (1) WO1996017869A2 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
PT852587E (pt) * 1995-09-28 2009-03-10 Yeda Res & Dev Péptidos sintéticos que inibem a actividade da il-6
US6217858B1 (en) 1997-02-11 2001-04-17 Hadasit & Medical Research Services & Development Company, Ltd. Pharmaceutical composition for treating hepatitis B virus (HBV) infection
GB9621095D0 (en) * 1996-10-09 1996-11-27 Imperial College Novel system
EP0983767B1 (fr) 1997-03-21 2008-09-10 Chugai Seiyaku Kabushiki Kaisha Substances servant à la prévention ou au traitement de la sclérose en plaques contenant comme principe actif des anticorps antagonistes contre le récepteur de l' IL-6
US7227837B1 (en) 1998-04-30 2007-06-05 At&T Labs, Inc. Fault tolerant virtual tandem switch
CA2237915A1 (fr) 1998-05-19 1999-11-19 Stephen Shaughnessy Traitement de l'osteoporose
EP1108435B1 (fr) 1998-08-24 2007-01-03 Chugai Seiyaku Kabushiki Kaisha Produits preventifs ou therapeutiques de la pancreatite contenant des anticorps contre il-6 receptor comme substance active
JP4799516B2 (ja) * 1998-08-24 2011-10-26 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する膵炎の予防又は治療剤
EP1206275B1 (fr) * 1998-11-05 2007-09-05 Omeros Corporation Solution d'irrigation et methode pour l'inhibition de la douleur et de l'inflammation
WO2001016166A2 (fr) 1999-08-27 2001-03-08 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Polypeptides comprenant des domaines de recepteur d'interleukine-6 se liant a un ligand, acides nucleiques correspondants, anticorps, compositions, et leurs procedes d'utilisation
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
AUPR769501A0 (en) * 2001-09-14 2001-10-11 Biomolecular Research Institute Limited Cytokine receptor 1
US20060165696A1 (en) 2003-02-24 2006-07-27 Chugai Seiyaku Kabushiki Kaisha Keio University Remedy for spinal injury containing interleukin-6 antagonist
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
AR046290A1 (es) 2003-10-17 2005-11-30 Chugai Pharmaceutical Co Ltd Agente terapeutico para el mesotelioma
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
WO2007043641A1 (fr) 2005-10-14 2007-04-19 Fukuoka University Inhibiteur de dysfonctionnement d'îlots transplantés dans un transplant d'îlots
WO2007046489A1 (fr) 2005-10-21 2007-04-26 Chugai Seiyaku Kabushiki Kaisha Agent therapeutique pour maladie de coeur
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
JPWO2007061029A1 (ja) 2005-11-25 2009-05-07 学校法人慶應義塾 前立腺癌治療剤
EP1990060B1 (fr) 2006-01-27 2016-09-28 Keio University Agents therapeutiques pour maladies associées avec neovascularisation choroïdale
JP5754875B2 (ja) 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
PE20081635A1 (es) 2007-01-23 2009-01-07 Chugai Pharmaceutical Co Ltd Agentes para suprimir la reaccion de rechazo cronica
KR101665729B1 (ko) 2008-06-05 2016-10-12 국립연구개발법인 고쿠리츠간켄큐센터 신경침윤 억제제
JP5904552B2 (ja) 2010-05-28 2016-04-13 国立研究開発法人国立がん研究センター 膵癌治療剤
EP2578231B1 (fr) 2010-05-28 2022-10-26 Chugai Seiyaku Kabushiki Kaisha Agent améliorant la réponse de lymphocytes t anti-tumoraux
EP3009518B1 (fr) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Procédé permettant de prédire le pronostic post-thérapie d'un patient atteint de sclérose en plaques à périodes progressives et rémittentes (spppr) et procédé permettant de déterminer l'applicabilité d'une nouvelle thérapie
EP2898896A1 (fr) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents pour utilisation dans le traitement de l'inflammation de la rétine
TWI805046B (zh) 2015-02-27 2023-06-11 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
WO2018203545A1 (fr) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Procédé de prédiction et d'évaluation d'un effet thérapeutique dans des maladies associées à il-6 et à des neutrophiles
EP3747469A4 (fr) 2018-01-31 2022-03-23 Motokazu Kato Agent thérapeutique pour l'asthme contenant un inhibiteur d'il-6
KR20210025054A (ko) * 2018-06-21 2021-03-08 샤턱 랩스 인코포레이티드 이형이량체 단백질 및 이의 용도
TWI868126B (zh) 2019-04-17 2025-01-01 國立大學法人廣島大學 以組合投予il-6 抑制劑與ccr2 抑制劑為特徵之泌尿器官癌的治療劑
CN110133241B (zh) * 2019-05-21 2022-05-27 中国食品药品检定研究院 一种测定重组人可溶性gp130-Fc融合蛋白生物学活性的新方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0591892A (ja) * 1991-10-02 1993-04-16 Chuzo Kishimoto Ｉｌ−６レセプター誘導体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0591892A (ja) * 1991-10-02 1993-04-16 Chuzo Kishimoto Ｉｌ−６レセプター誘導体

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE STRAND TPSD *
DATABASE WPI Week 9320, Derwent World Patents Index; AN 93-161739, XP002003861 *
LIAUTARD ET AL.: "Epitope analysis of human IL-6 receptor gp80 molecule with monoclonal antibodies", EUR. CYTOKINE NETWORK, vol. 5, no. 3, May 1994 (1994-05-01) - June 1994 (1994-06-01), pages 293 - 300, XP000571448 *
SALVATI ET AL.: "Interleukin-6 (IL-6) antagonism by soluble IL-6 receptor alpha mutated in the predicted gp130-binding interface", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 20, 19 May 1995 (1995-05-19), pages 12242 - 12249, XP000566420 *
TAGA ET AL.: "Interleukin-6 receptor and a unique mechanism of its signal transduction", COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, vol. 54, 1989, pages 713 - 722, XP002003860 *
YAWATA ET AL.: "Structure-function analysis of human IL-6 receptor : dissociation of amino acid residues required for IL-6-binding and IL-6 signal transduction through gp130", EMBO J., vol. 12, no. 4, 1993, pages 1705 - 1712, XP002003859 *

Also Published As

Publication number Publication date
IT1274350B (it) 1997-07-17
CN1139933A (zh) 1997-01-08
EP0742794A1 (fr) 1996-11-20
ITRM940794A1 (it) 1996-06-06
ITRM940794A0 (it) 1994-12-06
AU4186696A (en) 1996-06-26
WO1996017869A2 (fr) 1996-06-13
JPH09503232A (ja) 1997-03-31
CA2177837A1 (fr) 1996-06-07

Similar Documents

Publication Publication Date Title
WO1996017869A3 (fr) Antagonistes d'interleukine-6 (il-6)
ALS CNTF Treatment Study Group A double‐blind placebo‐controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis
Maurset et al. Comparison of ketamine and pethidine in experimental and postoperative pain
Chandra et al. Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial--the GONIP Trial.
CA2305799A1 (fr) Composition de traitement de la dependance a la nicotine contenant un antagoniste du recepteur a la nicotine et medicament antidepresseur ou anxiolytique
NZ305166A (en) 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles; preparation and medicaments
HUP0003280A3 (en) Peptides having apolipoprotein a-1 agonist activity, pharmaceutical compositions comprising thereof and their use to treat dyslipidemic disorders
SI0751129T1 (en) Substituted dihydrodibenzo(b,f)azepines, method for their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them
Seibel et al. Cyclosporine‐induced gingival overgrowth in beagle dogs
HK1027502A1 (en) Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
ATE547119T1 (de) Präventives oder therapeutisches mittel mit einem il-6-antagonisten als wirkstoff für durch sensibilisierte t-zellen vermittelte erkrankungen
HUP9904362A2 (hu) Eljárás felső légúti allergiás tünetek kezelésére hisztamin H1 és H3 receptor-antagonisták kombinációjával
WO1998008546A3 (fr) Combinaisons therapeutiques d'antagonistes de rar et d'agonistes de rxr
BR9709915A (pt) Composto composição farmacêutica utilização do composto e processos para o tratamento ou a prevençao de distúrbios fisiológicos asociados com um excesso de taquiquininas e para preparação do composto
CA2164689A1 (fr) Antagonistes du recepteur nk-1 et antagonistes du recepteur 5ht3 pour le traitement des vomissements
SI1010688T1 (en) Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
HUP0302333A3 (en) The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
NZ516477A (en) Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
GR3026600T3 (en) Human il-4 mutant proteins.
EP0426055A3 (en) Copolymers from lactic acid and tartaric acid, their preparation and their use
CA2132544A1 (fr) Antagonistes d'angiotensine ii utiles contre les troubles lies a une vitesse alteree de l'influx nerveux, particulierement dans le cas de la neuropathie diabetique
WO2000002551A3 (fr) Procedes et composes permettant de traiter la depression et d'autres troubles
AP2002002501A0 (en) Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
AU1583492A (en) Use of sigma receptor antagonists for treatment of amphetamine abuse

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95191457.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1995940401

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2177837

Country of ref document: CA

AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 1996 687490

Country of ref document: US

Date of ref document: 19961016

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1995940401

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995940401

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载